AR091838A1 - Acidos 5-aminotetrahidroquinolin-2-carboxilicos y su uso - Google Patents
Acidos 5-aminotetrahidroquinolin-2-carboxilicos y su usoInfo
- Publication number
- AR091838A1 AR091838A1 ARP130102566A ARP130102566A AR091838A1 AR 091838 A1 AR091838 A1 AR 091838A1 AR P130102566 A ARP130102566 A AR P130102566A AR P130102566 A ARP130102566 A AR P130102566A AR 091838 A1 AR091838 A1 AR 091838A1
- Authority
- AR
- Argentina
- Prior art keywords
- fluorine
- alkyl
- series
- difluoromethyl
- trifluoromethyl
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 5
- 229910052731 fluorine Chemical group 0.000 abstract 5
- 239000011737 fluorine Chemical group 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 3
- 229910052801 chlorine Inorganic materials 0.000 abstract 3
- 239000000460 chlorine Substances 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 abstract 1
- YCTMSIGDGYEBRJ-UHFFFAOYSA-N 5-amino-1,2,3,4-tetrahydroquinoline-2-carboxylic acid Chemical class N1C(C(O)=O)CCC2=C1C=CC=C2N YCTMSIGDGYEBRJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000006306 Cor pulmonale Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- -1 cyano, difluoromethyl Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se refiere a ácidos 5-aminotetrahidroquinolin-2-carboxílicos, a procedimientos para su preparación, a su uso para el tratamiento y/o la prevención de enfermedades así como a su uso para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades, especialmente para el tratamiento y/o la prevención de enfermedades cardiovasculares y cardiopulmonares. Reivindicación 1: Compuesto de la fórmula (1) en la que R¹ representa hidrógeno o flúor; L¹ representa etan-1,2-diilo o 1,4-fenileno; y A representa un grupo de la fórmula (2), (3) ó (4), en la que * indica el punto de unión respectivo con el resto de la molécula; L² significa alcanodiilo C₁₋₆ de cadena lineal; L³ significa una unión, -O-, -CH₂-, -CH₂-CH₂- o -CH=CH-; R² significa alquilo C₁₋₄, que puede estar sustituido hasta seis veces con flúor, o significa cicloalquilo C₃₋₆, que puede estar mono o disustituido, de manera igual o diferente, con un resto seleccionado de la serie flúor, difluorometilo, trifluorometilo y alquilo C₁₋₄, o significa un heterociclilo de 4 a 6 miembros que contiene uno o dos miembros heteroanulares iguales o diferentes seleccionados de la serie N(R⁴), O, S y S(O)₂ en la que R⁴ representa alquilo C₁₋₄ o alquilcarbonilo C₁₋₄ o en el caso de que N(R⁴) represente un átomo de nitrógeno anular por medio del cual el heterociclilo mencionado está enlazado con el grupo fenilo adyacente, no está presente, o significa un heteroarilo de 5 miembros que contiene uno, dos o tres heteroátomos anulares iguales o diferentes seleccionados de la serie N, O y S y opcionalmente puede estar condensado con un anillo fenilo, pudiendo el anillo heteroarilo y el anillo fenilo eventualmente condensado estar respectivamente mono o disustituidos, de manera igual o diferente con un resto seleccionado de la serie flúor, cloro, ciano, difluorometilo, trifluorometilo, alquilo C₁₋₄, difluorometoxi, trifluorometoxi y alcoxi C₁₋₄, o significa cloro; y R³A, R³B, R³C y R³D significan independientemente entre sí hidrógeno o un sustituyente seleccionado de la serie flúor, cloro, bromo, ciano, alquilo C₁₋₄, difluorometilo, trifluorometilo, alcoxi C₁₋₄, difluorometoxi y trifluorometoxi; así como sus sales, solvatos y los solvatos de las sales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12177284 | 2012-07-20 | ||
| EP13167967 | 2013-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091838A1 true AR091838A1 (es) | 2015-03-04 |
Family
ID=48914233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102566A AR091838A1 (es) | 2012-07-20 | 2013-07-18 | Acidos 5-aminotetrahidroquinolin-2-carboxilicos y su uso |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US8981104B2 (es) |
| EP (1) | EP2875003B1 (es) |
| JP (1) | JP6251259B2 (es) |
| KR (1) | KR102137517B1 (es) |
| CN (1) | CN104822661B (es) |
| AR (1) | AR091838A1 (es) |
| AU (1) | AU2013292046C1 (es) |
| BR (1) | BR112015001211B1 (es) |
| CA (1) | CA2879369C (es) |
| CL (1) | CL2015000120A1 (es) |
| CO (1) | CO7240369A2 (es) |
| CR (1) | CR20150020A (es) |
| CY (1) | CY1118588T1 (es) |
| DK (1) | DK2875003T3 (es) |
| DO (1) | DOP2015000012A (es) |
| EA (1) | EA028918B9 (es) |
| EC (1) | ECSP15001882A (es) |
| ES (1) | ES2616036T3 (es) |
| GT (1) | GT201500011A (es) |
| HR (1) | HRP20170185T1 (es) |
| HU (1) | HUE030540T2 (es) |
| IL (1) | IL236616B (es) |
| JO (1) | JO3343B1 (es) |
| LT (1) | LT2875003T (es) |
| ME (1) | ME02603B (es) |
| MX (1) | MX360863B (es) |
| MY (1) | MY172994A (es) |
| NZ (1) | NZ702977A (es) |
| PE (1) | PE20150350A1 (es) |
| PH (1) | PH12015500106B1 (es) |
| PL (1) | PL2875003T3 (es) |
| PT (1) | PT2875003T (es) |
| RS (1) | RS55651B1 (es) |
| SG (2) | SG11201408421TA (es) |
| SI (1) | SI2875003T1 (es) |
| TN (1) | TN2015000026A1 (es) |
| TW (1) | TWI598338B (es) |
| UY (1) | UY34918A (es) |
| WO (1) | WO2014012934A1 (es) |
| ZA (1) | ZA201409394B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1993360T3 (en) | 2005-12-28 | 2017-05-22 | Vertex Pharma | SOLID FORMS OF N- [2,4-BIS (1,1-DIMETHYLETHYL) -5-HYDROXYPHENYL] -1,4-DIHYDRO-4-OXOQUINOLIN-3-CARBOXAMIDE |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| US9290440B2 (en) | 2012-04-16 | 2016-03-22 | Toa Eiyo Ltd. | Bicyclic compound |
| PL2875003T3 (pl) * | 2012-07-20 | 2017-05-31 | Bayer Pharma Aktiengesellschaft | Nowe kwasy 5-aminotetrahydrochinolino-2-karboksylowe i ich zastosowanie |
| ES2603262T3 (es) | 2012-07-20 | 2017-02-24 | Bayer Pharma Aktiengesellschaft | Ácidos aminoindano-carboxílicos y aminotetralin-carboxílicos sustituidos y su uso |
| FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| AU2016258847A1 (en) | 2015-05-06 | 2017-11-16 | Bayer Pharma Aktiengesellschaft | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of Digital Ulcers (DU) concomitant to Systemic Sclerosis (SSc) |
| WO2017013010A1 (de) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
| CN109476589A (zh) * | 2016-07-22 | 2019-03-15 | 东亚荣养株式会社 | 青光眼治疗药 |
| EP3525778A1 (de) | 2016-10-11 | 2019-08-21 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| WO2019081353A1 (de) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Substituierte imidazopyridinamide und ihre verwendung |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| CN108218770A (zh) * | 2018-02-28 | 2018-06-29 | 南京波普生物医药研发有限公司 | 2-氯-7,8-二氢-6h-喹啉-5-酮的制备方法 |
| WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| JOP20200287A1 (ar) | 2018-05-15 | 2020-11-09 | Bayer Ag | بنزاميدات مستبدلة بـ 3،1- ثيازول-2- يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
| WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
| WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
| BR112021021188A2 (pt) | 2019-05-07 | 2021-12-14 | Bayer Ag | Compostos inibidores de masp e usos dos mesmos |
| EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
| EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
| US20230183181A1 (en) | 2020-05-20 | 2023-06-15 | Bayer Aktiengesellschaft | Process of preparing butyl-(5s)-5-({2-[4-(butoxycarbonyl)phenyl]ethyl}[2-(2-{[3-chloro-4'-(trifluoromethyl)[biphenyl]-4-yl]methoxy}phenyl)ethyl]amino)-5,6,7,8-tetrahydroquinoline-2-carboxylate |
| WO2023126438A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | Pharmaceutical dry powder inhalation formulation |
| EP4457215A1 (en) | 2021-12-29 | 2024-11-06 | Bayer Aktiengesellschaft | Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl] 2-(2-{ 3-chloro-4'-(trifluoromethyl)biphenyl-4- yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound |
| AU2022424376A1 (en) * | 2021-12-29 | 2024-07-04 | Bayer Aktiengesellschaft | Treatment of cardiopulmonary disorders |
| JP2025518350A (ja) | 2022-06-09 | 2025-06-12 | バイエル・アクチエンゲゼルシヤフト | 女性における駆出率が維持された心不全の治療に使用するための可溶性グアニル酸シクラーゼアクチベーター |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8004002L (sv) | 1980-05-29 | 1981-11-30 | Arvidsson Folke Lars Erik | Terapeutiskt anvendbara tetralinderivat |
| IL65501A (en) | 1981-05-08 | 1986-04-29 | Astra Laekemedel Ab | 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them |
| DE3718317A1 (de) | 1986-12-10 | 1988-06-16 | Bayer Ag | Substituierte basische 2-aminotetraline |
| DE3719924A1 (de) | 1986-12-22 | 1988-06-30 | Bayer Ag | 8-substituierte 2-aminotetraline |
| WO1990015047A1 (en) | 1989-05-31 | 1990-12-13 | The Upjohn Company | Therapeutically useful 2-aminotetralin derivatives |
| FR2659853A1 (fr) | 1990-03-22 | 1991-09-27 | Midy Spa | Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale. |
| AU1867095A (en) | 1994-01-10 | 1995-08-01 | Technion Research & Development Foundation Ltd. | 1-aminoindan derivatives and compositions thereof |
| ATE255888T1 (de) | 1998-06-01 | 2003-12-15 | Ortho Mcneil Pharm Inc | Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9827467D0 (en) | 1998-12-15 | 1999-02-10 | Zeneca Ltd | Chemical compounds |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10109858A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige halogensubstituierte Aminodicarbonsäurederivate |
| DE10109859A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige Aminodicarbonsäurederivate |
| DE10109861A1 (de) * | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| US20050032873A1 (en) | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
| GB0318094D0 (en) * | 2003-08-01 | 2003-09-03 | Pfizer Ltd | Novel combination |
| US7803951B2 (en) | 2005-03-30 | 2010-09-28 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| DE102005047946A1 (de) * | 2005-10-06 | 2007-05-03 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten |
| DE102005050377A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
| DE102006031175A1 (de) * | 2006-07-06 | 2008-01-10 | Bayer Healthcare Ag | Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur |
| WO2009023669A1 (en) | 2007-08-13 | 2009-02-19 | Janssen Pharmaceutica N.V. | Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof |
| EA201070339A1 (ru) | 2007-09-06 | 2010-10-29 | Мерк Шарп Энд Домэ Корп. | Активаторы растворимой гуанилатциклазы |
| EP2331498B1 (en) * | 2008-08-19 | 2016-11-09 | Janssen Pharmaceutica NV | Cold menthol receptor antagonists |
| DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| CA2803688A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| EP2708539A1 (de) | 2010-07-09 | 2014-03-19 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| EP2683710B1 (en) | 2011-03-10 | 2017-07-19 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
| US9290440B2 (en) * | 2012-04-16 | 2016-03-22 | Toa Eiyo Ltd. | Bicyclic compound |
| ES2603262T3 (es) | 2012-07-20 | 2017-02-24 | Bayer Pharma Aktiengesellschaft | Ácidos aminoindano-carboxílicos y aminotetralin-carboxílicos sustituidos y su uso |
| PL2875003T3 (pl) * | 2012-07-20 | 2017-05-31 | Bayer Pharma Aktiengesellschaft | Nowe kwasy 5-aminotetrahydrochinolino-2-karboksylowe i ich zastosowanie |
-
2013
- 2013-07-16 PL PL13744464T patent/PL2875003T3/pl unknown
- 2013-07-16 PE PE2015000049A patent/PE20150350A1/es active IP Right Grant
- 2013-07-16 HU HUE13744464A patent/HUE030540T2/en unknown
- 2013-07-16 KR KR1020157001058A patent/KR102137517B1/ko active Active
- 2013-07-16 RS RS20170110A patent/RS55651B1/sr unknown
- 2013-07-16 CN CN201380048579.2A patent/CN104822661B/zh active Active
- 2013-07-16 NZ NZ702977A patent/NZ702977A/en unknown
- 2013-07-16 PT PT137444642T patent/PT2875003T/pt unknown
- 2013-07-16 WO PCT/EP2013/065017 patent/WO2014012934A1/de not_active Ceased
- 2013-07-16 HR HRP20170185TT patent/HRP20170185T1/hr unknown
- 2013-07-16 ME MEP-2017-30A patent/ME02603B/me unknown
- 2013-07-16 EA EA201590251A patent/EA028918B9/ru not_active IP Right Cessation
- 2013-07-16 MY MYPI2015000125A patent/MY172994A/en unknown
- 2013-07-16 SG SG11201408421TA patent/SG11201408421TA/en unknown
- 2013-07-16 DK DK13744464.2T patent/DK2875003T3/en active
- 2013-07-16 JP JP2015522074A patent/JP6251259B2/ja active Active
- 2013-07-16 BR BR112015001211-6A patent/BR112015001211B1/pt active IP Right Grant
- 2013-07-16 SG SG10201700454PA patent/SG10201700454PA/en unknown
- 2013-07-16 LT LTEP13744464.2T patent/LT2875003T/lt unknown
- 2013-07-16 AU AU2013292046A patent/AU2013292046C1/en active Active
- 2013-07-16 ES ES13744464.2T patent/ES2616036T3/es active Active
- 2013-07-16 MX MX2015000739A patent/MX360863B/es active IP Right Grant
- 2013-07-16 EP EP13744464.2A patent/EP2875003B1/de active Active
- 2013-07-16 SI SI201330514A patent/SI2875003T1/sl unknown
- 2013-07-16 CA CA2879369A patent/CA2879369C/en active Active
- 2013-07-18 JO JOP/2013/0216A patent/JO3343B1/ar active
- 2013-07-18 US US13/945,675 patent/US8981104B2/en active Active
- 2013-07-18 AR ARP130102566A patent/AR091838A1/es active IP Right Grant
- 2013-07-19 UY UY0001034918A patent/UY34918A/es active IP Right Grant
- 2013-07-19 TW TW102125865A patent/TWI598338B/zh active
-
2014
- 2014-12-19 ZA ZA2014/09394A patent/ZA201409394B/en unknown
-
2015
- 2015-01-11 IL IL236616A patent/IL236616B/en active IP Right Grant
- 2015-01-14 PH PH12015500106A patent/PH12015500106B1/en unknown
- 2015-01-15 CO CO15007422A patent/CO7240369A2/es unknown
- 2015-01-16 CL CL2015000120A patent/CL2015000120A1/es unknown
- 2015-01-16 DO DO2015000012A patent/DOP2015000012A/es unknown
- 2015-01-19 TN TNP2015000026A patent/TN2015000026A1/fr unknown
- 2015-01-19 EC ECIEPI20151882A patent/ECSP15001882A/es unknown
- 2015-01-20 CR CR20150020A patent/CR20150020A/es unknown
- 2015-01-20 GT GT201500011A patent/GT201500011A/es unknown
- 2015-01-29 US US14/609,122 patent/US9688636B2/en active Active
-
2017
- 2017-02-03 CY CY20171100161T patent/CY1118588T1/el unknown
- 2017-05-19 US US15/600,132 patent/US10053428B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091838A1 (es) | Acidos 5-aminotetrahidroquinolin-2-carboxilicos y su uso | |
| PE20211501A1 (es) | Piridinonas anti-fibroticas | |
| CY1124726T1 (el) | Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv | |
| AR097631A1 (es) | Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos | |
| ES2722048T3 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| MX376271B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| ECSP16076566A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4 | |
| BR112015004111A2 (pt) | novos derivados bicíclicos | |
| PE20170331A1 (es) | Derivados quinolina como inhibidores smo | |
| EA201391822A1 (ru) | Новые производные пиридина | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| AR100984A1 (es) | Método para producir un compuesto heterocíclico fusionado | |
| UY34888A (es) | Inhibidores del virus de la hepatitis c | |
| EA201591064A1 (ru) | Новые производные пиридина | |
| AR081628A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| PE20160661A1 (es) | Compuesto de azapiridona y sus usos de los mismos | |
| UY35263A (es) | Compuestos terapéuticos | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| EA201591567A1 (ru) | Новые производные пиридина | |
| AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
| EA201591624A1 (ru) | Новые производные пиразола | |
| AR086482A1 (es) | Inhibidores de aldosterona sintasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |